The Binding Site Introduces Highly Purified Nucleosome Antigen -- MEDICA - World Forum for Medicine


The Binding Site GmbH

The Binding Site Introduces Highly Purified Nucleosome Antigen

Nucleosome Photo Graphic

The Binding Site Inc. is pleased to announce an expansion of its already broad offering of clinical and research products and services to now include the Nucleosome antigen manufactured by Arotec Diagnostics. Antibodies to Nucleosome, also referred to as Anti-Chromatin Antibodies, constitute one of the first autoantibody specificities found to be present in systemic lupus erythematosus (SLE).

The prevalence of Anti-Nucleosome Antibodies in SLE is of the order of 50-100%, and the Nucleosome has been identified as the initiating and driving the production of one or more antibodies in response to SLE. Anti-Nucleosome Antibodies are now considered to be a more sensitive marker for SLE than Anti-dsDNA Antibodies and a high Anti-Nucleosome Antibody titer has been reported to be indicative of lupus nephritis. Antibodies to Nucleosome have also been found, albeit at a lower prevalence than in SLE, in a number of other autoimmune diseases, such as systemic sclerosis, Sjogren's syndrome, mixed connective tissue disease and patients with autoimmune hepatitis Type I.

As such, medical laboratory professionals, clinical researchers and manufacturers of in-vitro diagnostic (IVD) immunoassay kits and diagnostic tests for auto-immune conditions are certain to benefit from the availability of this product. Derived and sourced from bovine thymus of New Zealand origin, this Nucleosome antigen exhibits exceptional degrees of activity and specificity, while demonstrating a product purity level in excess of 90% as assessed by SDS gel electrophoresis. Expressly designed for use as a critical component in solid phase ELISA-based immunoassay test procedures, the product also features exceptional shelf life stability and lot-to-lot consistency. The antigen is available in three separate operator-oriented packaging fill formats of 1.0mg, 0.5mg and 0.2mg, with customer distinct and bulk packaging configurations also being available.

The Binding Site, Inc. serves the in-vitro diagnostic and life science markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 5889 Oberlin Drive – Suite 101, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: Please visit our website at